+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating treatments for men with metastatic prostate cancer, a condition where cancer has spread beyond the prostate to other parts of the body. This phase III trial compares standard systemic therapy alone versus standard systemic therapy combined with definitive treatment of the primary tumor, such as prostate removal surgery or radiation therapy. The goal is to see if adding these local treatments improves survival and delays cancer progression. Participants begin with an induction period of 22 to 28 weeks receiving one of six forms of standard systemic therapy, which may include hormone therapies like goserelin or leuprolide injections, oral medications such as abiraterone or bicalutamide, or chemotherapy with docetaxel. After induction, participants are randomly assigned to continue systemic therapy alone or to receive systemic therapy plus prostatectomy within 8 weeks or radiation therapy within 4 weeks. The study includes tissue and blood sample collection for future research. Throughout the trial, participants have regular assessments including physical exams, laboratory tests measuring PSA and testosterone levels, and imaging scans to monitor disease status. Patient-reported quality of life related to urinary function, pain, and physical abilities is also evaluated over several years. After treatment, participants are followed for up to eight years to track overall survival, progression-free survival, and local symptom progression, providing a comprehensive understanding of treatment effects over time.

Age: 18Years +MALEPhase 3
338 locations